2019
Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Chan C, Blankestijn P, Dember L, Gallieni M, Harris D, Lok C, Mehrotra R, Stevens P, Wang A, Cheung M, Wheeler D, Winkelmayer W, Pollock C, Participants C, Abu-Alfa A, Bargman J, Bleyer A, Brown E, Davenport A, Davies S, Finkelstein F, Flythe J, Goffin E, Golper T, Gómez R, Hamano T, Hecking M, Heimbürger O, Hole B, Hothi D, Ikizler T, Isaka Y, Iseki K, Jha V, Kawanishi H, Kerr P, Komenda P, Kovesdy C, Lacson E, Laville M, Lee J, Lerma E, Levin N, Lichodziejewska-Niemierko M, Liew A, Lindley E, Lockridge R, Madero M, Massy Z, McCann L, Meyer K, Morton R, Nadeau-Fredette A, Okada H, Perez J, Perl J, Polkinghorne K, Riella M, Robinson B, Rocco M, Rosansky S, Rotmans J, Roblero M, Tangri N, Tonelli M, Tong A, Tsukamoto Y, Tungsanga K, Vachharajani T, van Loon I, Watnick S, Weiner D, Wilkie M, Zakharova E. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 96: 37-47. PMID: 30987837, DOI: 10.1016/j.kint.2019.01.017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEnd-stage kidney diseaseDialysis initiationKidney diseaseModality choiceGoals of careNumber of patientsPatient-centered goalsDiverse health care systemsHealth care jurisdictionsAreas of controversyHealth care systemControversies ConferenceMaintenance dialysisDialysis modalityPatient goalsPatient educationIndividualized carePatient involvementPatient experienceGlobal outcomeCare systemDialysisPatientsOutcomesDisease
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment